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A B S T R A C T
Rodent models of human diseases that accurately and reproducibly capture their pathology are key tools in
furthering our understanding of the mechanisms behind these diseases and in the development of novel treat-
ment approaches. However, pre-clinical studies in rodents are often criticised for the relative lack of replication
and success upon translation to humans. Animal models of neurodegenerative diseases (and other CNS condi-
tions) are very complex, often with multifactorial inputs into their development and progression. This com-
plexity is a significant challenge. In addition to this, there are often concerns raised about the conduct, analysis
and interpretation of the model results. This review focuses on Alzheimer’s disease as a representative neuro-
degenerative disorder and will examine disease model end-points, in particular, behavioural phenotyping which,
while appearing relatively straightforward, has the potential to be poorly conducted and the results mis-
construed. This review uses a sample of the literature to illustrate the breadth of techniques used in behavioural
assessment of Alzheimer’s disease models, highlight the complexity, illustrate some procedural, interpretational
and translational issues and provide recommendations to improve conduct of pre-clinical testing with the hope
that this may lead to more consistency and translational success.
1. Introduction
Neurodegenerative diseases encompass a range of disorders that
affect our brain and may include Parkinson’s, Alzheimer’s, and
Huntington’s disease, as well as other disorders, such as prion disease,
motor neurone disease and spinal muscular atrophy. In these condi-
tions, cognitive and/or physical functionality progressively decreases in
parallel with the neural degeneration, leading to severe disability and
death. With an ageing population worldwide, the prevalence of neu-
rodegenerative diseases is expected to rise over the coming years, re-
presenting a significant burden on health systems. According to the EU
Joint Programme – Neurodegenerative Disease Research (JPND), de-
mentias are responsible for the greatest burden of neurodegenerative
diseases. For example, it is estimated that there are currently almost 47
million people worldwide living with dementia, the most common form
of which is Alzheimer’s disease (AD) [1]. Although the various neuro-
degenerative disorders have different clinical presentation and patho-
logical changes, some of the underlying processes are common, such as
protein deposition, mitochondrial dysfunction and excitotoxicity [2–4].
However, the process of neurodegeneration is complex and multi-
factorial and as a result, there are still no treatments to ‘cure’ AD or
other neurodegenerative diseases. Despite this, there is significant on-
going research to try and better understand the pathological mechan-
isms so that new treatments and strategies can be developed.
Animal models form a critical experimental, pre-clinical step in
order to further our knowledge of neurodegeneration, as well as, de-
veloping and testing treatments. The models aim to represent the par-
ticular disease in the animal, which then allows insights into the pa-
thophysiology of the diseases. In addition to this, they are important in
the assessment of efficacy of putative therapeutic agents before con-
ducting human trials. This translation from animal models into humans
has represented a significant challenge and there are far too many
supposed treatments that have failed to be effective in humans. This
failure is across all of the neurodegenerative conditions from
Alzheimer’s disease, where the much heralded anti-Aβ (beta-amyloid
peptide) antibodies failed in clinical trials [5], to neuroprotection fol-
lowing cerebral ischaemia and the failure of NXY-059, a free radical-
trapping agent, which showed a lack of efficacy in the Stroke Therapy
Academic Industry Roundtable (STAIR) II trial [6]. One often men-
tioned reason for this translational failure is the poor design and re-
porting of pre-clinical studies (for review see [7]), leading to a lack of
reproducibility and bias in reporting results [8,9]. However, as
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mentioned above, it must be remembered that the complexity and
multifactorial nature of neurodegenerative diseases is a significant
challenge in translating results from the lab to the clinic. On the flip
side, many clinical trials have not paid sufficient attention to the lim-
itations of animal studies. This is evident in the stroke treatment trials
whereby, for practical reasons, patients cannot be treated with the
therapeutic agent inside the same time window (often 30–60min post-
ischaemia in animal studies) [10]. In order to increase the potential
success of treatments translated from animals to humans, the conduct
and reporting of animal studies needs to be improved. In addition, there
are a number of key factors, applicable across all in vivo studies that
should be considered. In this review, we will illustrate the general
considerations before looking at AD in detail and some of the issues in
the behavioural testing in AD models.
2. Key considerations in pre-clinical models of neurodegeneration
One of the key elements to improve the translation is that animal
models must demonstrate validity. There are many applicable types of
validity, including face and construct validity, whereby the behaviour
of the animals mimics that of the condition (face validity) with a the-
oretical underpinning, such that the pathology, for example, is similar
to that in patients (construct validity) [11]. However, more relevant in
this review are internal and external validity. If an animal experiment
has sufficient internal validity this means that, if investigating the effect
of a novel treatment, the differences measured between groups of ani-
mals may be attributed to the novel treatment. Internal validity can be
assured by careful study design and the minimisation of bias. The ex-
ternal validity refers to the extent to which a study reflects the disease
in the human. Therefore, the closer a model is to the human condition,
the better. A lack of external validity has been a factor in the failure of
some treatments investigated for stroke whereby animals used in stroke
studies are generally young and healthy but the patients who suffer a
stroke often have co-morbidities, including hypertension or diabetes
[12].
The choice of species, and indeed strain, is also a very important
consideration. There is a large body of evidence showing the differences
between, for example, rats and mice. While there is anatomical simi-
larity between the brains of rats and mice, differences have been shown
in neurotransmitter functions and localisation [13,14]. Furthermore,
the rate of hippocampal neurogenesis has been shown to be greater in
rats compared to mice and the newly generated cells are more likely to
survive long-term and become involved in behaviour [15]. Similarly,
while the vast majority of behavioural tests were originally designed for
rats, they are now also used for mice on the assumption that the be-
haviour will be the same. However, species differences have been
shown in, for example, water maze performance with mice performing
more poorly than rats and also in tests of effort based decision making
[16–18]. It is also significant to note that there are differences in be-
haviour between different strains of rodents. Much work has been done
to look at different strains of rodents and the subtle differences in be-
haviour between them, which should be taken into account in model-
ling a disease in vivo [19,20]. For example, in the Morris water maze,
some mouse strains are able to learn to find the platform more effec-
tively than other strains [21].
Finally to add to the complexity in choosing the species and strain of
animal for in vivo modelling, the gender is also important. There is
evidence that the female brain responds to steroid hormones differently
than the male brain which may impact stress responses and other be-
haviours [22]. Male mice have demonstrated better learning than fe-
male mice on both the working and reference memory components of a
water-based radial arm maze task [23]. Furthermore, gender based
differences in neurogenesis have been seen with steroid hormones
modulating neurogenesis which may subsequently impact cognition
and stress [24].
These animal-based factors have a direct impact on the behavioural
phenotype of a rodent. However, there are also environmental and
human effects that can impact. For example, there is much evidence
that differences in animal housing, both cages and their environment
can greatly influence emotional responses and learning and memory in
rodents [25,26]. Similarly, work by López-Aumatell and colleagues
[27] demonstrated an experimenter effect on measures of anxiety in
mice and other work has shown that handling of rodents can have an
impact on responses to pharmacological treatment in the elevated plus
maze test of anxiety [27,28]. In order to successfully translate results
from the animal to the clinic, there must be consistency in approaches
and results in animal experiments. One study that clearly illustrates the
difficulty with environmental influences was carried out by Crabbe and
colleagues [29]. They examined six different mouse behaviours across
three different laboratories, while standardising all protocols, apparatus
and animal environment yet still showed significant differences in test
results between the labs.
What is clear from this is that there are a number of considerations
that need to be taken in to account regarding in vivomodelling. Coupled
with the complexity of neurodegeneration, the plethora of different
models that can be chosen from and the specific phenotypic measures,
the use of animals in modelling CNS disorders is something that has to
be done carefully. Given this range and complexity, it is difficult for one
review to deal comprehensively with neurodegeneration, or even be-
havioural testing, as a whole. Consequently, we have focussed on
Alzheimer’s disease and more specifically the behavioural assays that
are utilised with AD models.
3. Alzheimer’s disease
Alzheimer’s disease (AD) is the most common form of dementia,
accounting up to 60–70% of dementia case [30]. It is a devastating
neurological disorder that affects an estimated 47 million people
globally [31]. Worse than this, this figure is set to increase to 135.46
million by 2050. It is a global epidemic, not confined to Western po-
pulations; 63% of people with dementia live in low- and middle-income
countries where support and social structures are often limited [31].
Furthermore, the disease is progressive, with the numbers of people
living with dementia increasing with increased life-span: the numbers
doubles with every 5.9 years increase in age, from 3.1/ 1000 person
years at age 60–64, to 175.0/ 1000 person years at age 95+ [31].
Dementia and cognitive impairment are the leading cause of disability
and dependence in older adults, with patients progressively unable to
carry out routine but essential daily tasks, as well as, being unable to
meet personal care needs [32]. The earliest symptoms of AD are im-
pairments in memory, specifically episodic memory (a memory related
to a particular event in one’s life; when something took place, where did
it occur, what happened and who was present) [30], followed by de-
clarative (explicit memory for facts and events, such as knowing the
capital of France) and non-declarative memory (implicit memory for
motor habits and skills, such as riding a bicycle). In addition to memory
impairments, other cognitive domains such as complex attention, ex-
ecutive functioning, language, perceptual-motor function and social
cognition form the basis of diagnosis of dementia (or neurocognitive
disorder (NCD) - Diagnostic and Statistical Manual of Mental Disorders
(DSM-5) [33]).
At the neural level, AD is characterised by the presence of beta-
amyloid peptide (Aβ) plaques that accumulate outside the cell and in-
tracellular neurofibrillary tangles, which, in turn can lead to neural
death. Beta-amyloid is a small peptide that is cleaved from the larger
amyloid precursor protein (APP), which outside accumulates cells as a
result of aberrant processing [34]. Intracellular neurofibrillary tangles
are composed of hyperphosphorylated tau protein, a microtubule-as-
sociated protein (MAP), that under normal circumstances helps in the
transport of organelles within the neuron as well as aiding in micro-
tubular assembly [35]. However, with AD, tau accumulates in a hy-
perphosphorylated tangled form in the soma and neurites of the neuron
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[30]. Neurofibrillary tangles are strongly associated with cognitive
decline and tend to show a specific pattern of spread. Tangles first
appear in the entorhinal cortex and hippocampal regions, before
spreading to the amygdala and the anterodorsal thalamus. From these
regions, tangles reach other cortical areas causing gross neurodegen-
eration [36].
Most animal models of AD have been developed either through
genetic means or by the direct central administration of β-amyloid. In
doing so, these models try to mimic the pathological hallmarks of AD
and the cognitive decline. Intracerebral infusion of β-amyloid results in
learning and memory deficits, as well as, many of the neuropathological
hallmarks of Alzheimer’s disease, such as nueroinflammation and mi-
croglial activation [37]. However, one limitation of the infusion models
is that the level of β-amyloid in the rodent brain is much greater that
would be seen in the brain of Alzheimer’s disease patients. Genetically
modified models (primarily mice) are excellent for establishing patho-
histological changes that often map cognitive impairments, as well as,
showing age-dependent development of neuropathology. For example,
the 5XFAD and APP/PS1 models show amyloid plaques, synaptic de-
generation and cellular death. In addition, these models develop cog-
nitive deficits [30]. The APP/PS1 model show reference memory defi-
cits at 6 months of age and persist after this; the model also shows
spatial working memory impairments earlier, at 3 months of age
[38,39]. Working memory deficits also seem to appear by 3 months in
the 5XFAD model [40]. However, some mouse models have shown
cognitive decline prior to amyloid plaques in the CNS [41,42]. For
example, King and colleagues showed that the APPSW transgenic mouse
exhibited early cognitive deficits, prior to amyloid plaque formation
[43]. In addition, these aforementioned models lack tau pathology – a
critical element in understanding AD [30]. Other models, such as the
triple-transgenic AD (3xTgAD) mouse, do show region-specific Aβ
plaques and tangles [44]; in addition, this model develops cognitive
impairments, including associative learning deficits at 3–5 months of
age, followed by working memory impairments at 6 months [39].
While there are different methods used to model AD, which we will
not discuss here, the common denominator for these (and most of the
neurodegenerative disorders) is behaviour. Behavioural tasks are rou-
tinely used to assess the extent or progression of neurodegeneration and
the impact of potential therapeutic agents. In this review, we examine
some of the more commonly used behavioural tests in AD and illustrate
some differences between nominally identical tests that may confound
the experiments and contribute to poor translation of results.
4. Behavioural assays commonly used with models of AD
To give a representative sample of the type of behavioural tasks that
are commonly used with AD models, we conducted a brief search of the
published literature. The intention was not to sample everything, thus
producing a systematic review, but rather to obtain a representative
sample of behavioural tasks used in AD models. The search strategy
involved the use of two English language databases, namely PubMed
and ScienceDirect, in February 2019. The search terms used were
‘Alzheimer’s disease’, ‘Behavioural tasks’ and ‘Animals’ within the years
from 2010 to 2018. Eighty-two articles were initially identified fol-
lowing the removal of repetitions. From this, a number of articles were
not included as they were not directly relevant to our search criteria or
the full text was unavailable; we were then left with 52 publications.
We examined each of these papers and identified the species, sex, AD
model, the behavioural task used and the functional domain associated
with the task. From this, we found that the majority of papers examined
cognitive functioning, as might be expected (44 papers), which were
often combined with examination of other domains including general
exploration (20 papers), motor functioning (15 papers) and anxiety (10
papers). Other behaviours such as sensory-motor gating, social inter-
action/discrimination, olfaction and visual discrimination were also
examined but with much less frequency (Fig. 1a).
Within the cognitive domain the majority of researchers used the
Morris water maze ([45] & Fig. 1a & b left) and this was used primarily
as a test of spatial/reference memory and spatial working memory (e.g.
[46] and Fig. 1a). The water maze task involves animals being placed
into a pool of water for a number of trials. As rats/mice generally find
water aversive, they try to escape it. Somewhere in the pool, hidden just
below the surface, is a small platform, which the animals can find and
escape on to. As the platform is invisible to the animal while swimming,
it must use the various cues in the environment to find and recall the
location of the platform [47]. The escape latency (i.e. the time to find
the platform) and other parameters are used as a measure of spatial
learning and memory. Depending on the training protocol, the water
maze can also be used to examine spatial working memory and pro-
cedural memory [48]. For example, to test spatial working memory,
many authors keep the platform location in the same position across
trials within a day but change its position each day. Given that lesions
of the hippocampus impair learning in this task [49,50], it measures
important clinical features of AD, especially memory. Furthermore, the
water maze is simple to use, is well validated and is a relatively cheap
piece of equipment. Consequently, it is a very popular task in models of
AD with most showing deficits (for example [51] with 3xTg-AD mice
[52]; with APP/APLP2 double knockout (cDKO)). The radial arm maze
and the radial water maze are also popular tasks to test spatial working
memory [53]. The radial arm maze is an apparatus with several arms
emanating from a central platform. At the end of each arm there is a
food well which can contain a food reward. The animal must obtain the
food from each arm, however the key feature is that on any given trial
the animal must recall which arm it has previously visited and which
arms still contain food. Deficits in these tasks have also been reported in
various AD models including APP/PS-1 double knock-in [54] and
PLB1Triple knock-in mice [55].
From our sample, the second most popular cognitive task used is the
novel object test (Fig. 1a & b middle). This task is also very simple to
implement and relies on an animal’s innate curiosity and natural in-
stinct to explore; it does not rely on the need to find a reward or escape
from an aversive stimulus. This task typically consists of three separate
phases; an animal is initially placed into an arena for a period of time,
allowing it to explore and get used to the environment (habituation
trial). Following this, the animal is allowed to explore the same arena
which now contains a number of objects (training trial) - typically 2
objects. Then after a period of time, one of the objects is replaced with a
novel one (test trial). The time spent by the animal on this trial ex-
ploring the novel object in comparison to the old one(s) is used as a
measure of memory and recognition [56]. Deficits in this task have also
been shown in a variety of AD models (for example [57] in scopola-
mine- and beta-amyloid peptide (Aβ)-induced amnesia models). The Y/
T-maze is another popular test and consists of three arms and a single
intersection. The task relies on the animal’s natural tendency to alter-
nate arms when exploring. It is commonly used to test spatial working
memory as lack of alternation indicates a deficit, failing to recognise the
previously visited arm [58].
Although contextual conditioning and passive avoidance tasks rely
on the animal’s ability to recognise and avoid a certain location due to
the presence of an aversive stimulus, these tasks are used to examine
long-term memory rather than as a test of anxiety (see discussion
below). In the simplest version of the task, animals are allowed to freely
explore two chambers on the first day of testing. On the second day, a
shock is administered to the feet of the animal in one of the chambers.
After a period of time (usually 24 h), the animal is placed into the
chamber where no shock was given. If remembered, the animal will
avoid entering the ‘shocking’ chamber and the time taken to enter this
chamber is a good indicator of memory. Mostafa and colleagues [59]
have shown that metformin ameliorated memory deficits on the passive
avoidance task in their scopolamine-induced amnesia model of AD.
Other tasks that examine cognitive flexibility, attention, executive
functioning and episodic memory are rarely examined (see discussion
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below), despite being critical clinical features of AD.
Within the general exploration domain, the open field task is very
popular. Researchers in the majority of the articles examined (20 pa-
pers) used it to examine motor movement, anxiety, as well as, general
activity. The task is very simple requiring little equipment and tech-
nology, which probably accounts for its popularity. In this task, animals
are placed into an arena and monitored over a set period of time. The
distance moved, time spent moving, the number of times the animal
grooms or rears, and the time spent in various locations of the arena can
all be measured. An animal that remains at the side of the arena and
moves very little may indicate issues of motor and/or anxiety. The
opposite may also be observed, such as, the hyperactivity found by
Maroof et al. in their AβPPswe/PS1ΔE9 mice [60]. Other tests of gen-
eral exploration and species-specific activity such as marble burying are
seldom examined (see [61]), despite that such tasks may equate with
various activities of everyday living measured in the clinic [62].
Motor functioning can be assessed more formally through a variety of
tasks with the most popular of these, from our sample papers, being the
rotarod, the balance beam and various tests of grip and suspension. The
rotarod consists of a rod rotating on its longitudinal axis. The animal is
placed onto the rod, which then slowly rotates. The rotation continues
for a set period of time or, as in the accelerating version, the speed of
rotation increases over the course of a few minutes. The time spent by
the animal on the rod before falling off is taken as a measure of balance.
A simpler test of balance involves a narrow beam up to 100 cm in length
(for mice, for rats a longer beam can be used) that is elevated and re-
quires the animal to traverse its length within a set period of time. Some
AD models, including the 5xFAD mouse model, show impaired balance
and motor co-ordination, and these animals are quicker to fall off the
balance beam in comparison to wild types [63]. Measuring the time
that an animal can hang onto a grid or piece of wire while suspended at
a height can be used as a good indicator of grip strength. Again, O’Leary
[63] found that 5xFAD mice were faster to fall when compared to wild
type (see also [64]). Other useful measures of motor impairment used
with AD models include gait analysis (looking at shuffling behaviour &
stride length, in 5xFAD mice [63]) and general monitoring of locomo-
tion in an activity chamber (also with 5xFAD mice [65]).
Anxiety can also be tested by using a variety of tasks but the most
popular one used from our sample (excluding the open field task) is the
elevated plus maze (8 papers, Fig. 1a). The apparatus consists of two
open arms (typically for mice, 30 cm in length and 5 cm wide) and two
closed arms (with same length and width and 15 cm high) extending
from a common central platform. The whole apparatus is elevated
above the ground (see Fig. 1b right). The task relies on the animal’s
propensity to avoid open spaces. The animal is usually allowed a short
period of time to explore the apparatus; the number of entries and the
Fig. 1. a Frequency of tasks used in the articles sampled, separated by the domain being tested. b: Left. Photographs of the water maze (left) with hidden platform
located below the water surface. Picture obtained with permission from Hamilton & Rhodes (2015) Prog Mol Biol Transl Sci. 135:381-406. Middle. A photograph of
two typical objects (tower of Lego bricks and a flask filled with sand) used in an object exploration task. Picture obtained with permission from Leger et al. (2013) Nat
Protoc. 8(12):2531-7. Right. Photograph of elevated plus maze. Picture obtained with permission from Walf & Frye (2007) Nat Protoc, 2, 322–328.
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time spent by the animal in the closed arms compared to the open arms
can be examined. Although, Ardestani and colleagues [65] did not
observe any deficits in 9-month old 5XFAD mice in the elevated plus
maze, aged 3xTg-AD mice have been demonstrated to show a higher
level of fear and anxiety using the same task [66]. Some researchers
also use the light/dark box to examine issues relating to anxiety. The
apparatus consists of two Perspex chambers; one chamber is brightly lit
while the dark compartment is covered and dim. Both chambers are
connected by a small opening at floor level. The amount of time the
animal spends exploring the two chambers is noted, as are the number
of light-dark transitions (a high number of transitions being indicative
of lower anxiety). Again, anxious animals tend to avoid bright open
spaces so will spend more time in the darker chamber; however, Plu-
cińska & Crouch [67] found that their model animals remained sig-
nificantly longer in the light chamber, suggesting reduced anxiety-re-
lated behaviour.
Other less common behavioural tasks that have been used with AD
models include a social discrimination task (5XFAD mice [65]). During
the first part of this task an unfamiliar mouse is placed in stainless steel
wire grid cup in one part of the cage (an empty cup is placed on the
opposite side). A test animal is free to explore around the entire area
and can sniff and interact with the mouse in the cup. During the second
phase, the mouse in the cup is moved to the opposite cup, while a new
unfamiliar mouse is placed under the original cup. The time spent by
the test mouse interacting with this new unfamiliar mouse compared to
the previous mouse is a measure of social interaction and discrimina-
tion. One of the earliest signs of AD is impairment in olfactory func-
tioning [68], yet very few animal models have examined this. One
study by Xu et al. [69] showed that Tg2576 mice were impaired in
odour memory but not with odour discrimination, suggesting that this
might be a useful measure that could be extended to other models.
5. Adequacy of behavioural tasks
Behaviour by its very nature is multifaceted and complex, as such it
is difficult to break down into constituent elements for any given si-
tuation. If we take memory as an example, there are different types (e.g.
declarative, procedural, working, etc), which in turn can be sub-di-
vided; declarative memories can be episodic or semantic in nature.
Some memories can have both an episodic and semantic component; for
example, spatial memory can have an episodic element (e.g. recalling a
location wherein an event took place) and a semantic element (e.g. my
house is located beside the park). Memories can rely on multiple senses
(olfactory, visual, auditory, etc.); they can span time – from a few
minutes to a life time; they can have different storage capacities, and
they can rely on different neural structures. A single task, therefore, can
not capture all elements of a particular behaviour. Even if we were to
try and capture most aspects of the behaviour (such as memory) we
would be overwhelmed by the amount of tasks we would need to em-
ploy - even if such tasks existed. Despite this seemingly pessimistic
view, many ingenious tasks have been used very successfully to capture
a wide-variety of behaviours and sub-behaviours, and these have also
been applied to various models of neurodegeneration including AD. In
the following sections we discuss the various tasks used in AD animal
models but highlight how some of them are open to interpretational,
translational and procedural issues.
5.1. Interpretational issues
One of the difficulties with some commonly-used behavioural tests
is that they are open to interpretation, it is often difficult to know what
exact behaviour is being examined by a particular task. Furthermore,
different authors use the same task to measure different behaviours. For
example, the Open Field test (described above) is a simple, easily ad-
ministered test, in which the animal is free to explore an open en-
vironment for a specified period of time. The animal can easily be
tracked using video-tracking software or certain behaviours can be
manually recorded by the experimenter. The test has been used for a
range of behaviours including the examination of general exploration
and activity, as well as, specifically allowing an animal to habituate to
an environment, before the introduction of objects (as in the case of the
object recognition task [70]). More often, especially in examining
models of AD, the task has been used to examine both anxiety [71] and
locomotion [63] behaviours, as well as general exploration. The time
spent by the animal moving/not moving, the time spent by the animal
in certain parts of the environment (e.g. at the side or in the open), as
well as changes in other natural behaviours (times rearing, grooming)
can be indicative of a deficit in the model but the difficulty is defining
the precise nature of this deficit.
The Passive Avoidance task is another important test in AD models
and is traditionally used to examine learning and long-term memory
[58]. In the task animals are required to avoid an environment in which
an aversive stimulus (e.g. a shock) has been previously administered.
Typically, the task is used in AD models to assess deficits in mnemonic
functioning [72]. However, passive-avoidance is also a fear-motivated
task [73]. Animals are conflicted to avoid an environment that they
would naturally prefer (e.g. a dark chamber). This approach-avoidance
choice relies not only on memory but motivation and fear too. Fur-
thermore, to complicate matters many authors use the passive-avoid-
ance task as a test of non-spatial memory [74]; this is despite the im-
portant role of context and location in the task. Other researchers use
the task to test memories at various intervals (e.g. at 24 h [75] or 48 h
and 1 week retention [66]). Given that different memories recruit dif-
ferent structures across time [76] and that some memory systems are
quickly impaired, while others remain spared, careful consideration
should be given to why and how a particular task, like the passive-
avoidance test is used. Furthermore, given the analogy between passive
avoidance and the Claparède phenomenon in AD patients (whereby an
aversive event could be recalled even if the patient’s short-term
memory was impaired), caution should be exercised if considering the
passive avoidance test [77].
Spatial memory deficits are key characteristics of AD [34]. Given
that brain areas such as the entorhinal cortex, hippocampus and ante-
rodorsal thalamus are heavily involved in spatial navigation [78,79], as
well as, being some of the first structures affected by AD pathophy-
siology [80], it is not surprising that many authors recently have sug-
gested that spatial navigation deficits have the potential to detect un-
derlying pathophysiology in Mild Cognitive Impaired (MCI) and pre-
clinical AD [34]. The water maze task, which requires animals to search
for a hidden platform located in a pool of water by using landmarks in
the environment, is considered the ‘gold standard’ for spatial navigation
and memory [45]. It is a task that depends on an intact hippocampus
[49,50] and has been used as the main cognitive test in AD models in
the majority of the papers that we analysed (for example [58,59]).
Aside from the procedural issues of the water maze procedure (dis-
cussed below), most authors do not consider adequate control measures
for behaviour in this well-validated task, and any results obtained
therefore may be open to interpretation. For example, if an AD animal
model does not find the hidden platform as quickly as the wild-type,
does this automatically suggest that the model mouse has impaired
spatial memory? The water maze task relies on many behaviours aside
from spatial memory – animals must be able visualise external cues,
they must be able to swim normally, they must be motivated to find the
platform and not be too distressed. Age [81], motor and visual im-
pairments [82] and stress [83] can all lead to a poor water maze per-
formance; many of these aspects are not directly related to AD, are not
the primary behaviour of interest by the researcher but yet may be a
characteristic of the particular model used. Work by Spencer and col-
leagues, for example, showed that the cause of failure in the Morris
water maze by aged rats, was due to retinal degeneration [84]. One
possible way to control for this would be to use cue training to exclude
affected rodents [85]. Hyperactivity and hypoactivity have also been
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reported in a number of models including APP695SWE (Tg2576) and
APP770SWE, respectively [86–88]. In some models, hyperactivity has
been shown to directly affect water maze performance. For example,
Baeta-Corral & Giménez-Llort [51] showed that escape latency, distance
and speed in finding the hidden platform were all affected by hyper-
activity in 3xTg-AD mice. A recent simple water maze control task
developed by Barry & Commins [89] may prove a useful method to
separate spatial learning from other characteristics, including motor
activity and stress in AD models, and aid in the interpretation of any
deficits observed.
5.2. Translational issues
Clearly the goal of any animal disease model is to try and match it,
as closely as possible, to what occurs in humans. Götz and colleagues
[30] offer a nice account of what to expect in a good animal model for
AD. In sum, the authors suggest that models should express the main
cellular features of AD, including neurodegeneration, plaques, neuro-
fibrillary tangles, and changes along specific molecular pathways.
These histopathological features should be initially confined to the
specific brain regions before spreading to other brain regions, mapping
onto the progression in humans. Furthermore, any cognitive symptoms
observed in humans, which are many, should been also seen in the
animal model, and the occurrence of such deficits should be again
linked to the progression of the disease. The question asked here is
whether the behavioural tasks used in animal models and the cognitive
functions that they purportedly test are matched with those used in the
clinic and the deficits observed in patients.
First, many tasks used in AD models may not be directly matched to
tests carried out in the clinic. The passive avoidance task is a good test
for long-term memory in animals; however, can this test be directly
compared to long-term memory or other memory tests typically used in
the clinic? Avoiding a particular location as a result of a single fearful
occurrence may not be a common occurrence among those with AD.
Given ethical and other considerations, this paradigm may not be ap-
propriate to use as a test with a patient sample. The novel object re-
cognition task has also been used in many animal models, primarily to
examine both short and long-term object memory [70]. Although object
recognition relies on structures of the medial temporal lobe (including
the perirhinal cortex [90] and the hippocampus [91]) and is impaired
in AD [92], some studies have reported that AD patients are as accurate
as controls in object detection [93]. In the clinic, memory is often tested
initially through a variety of general tests of cognitive impairment in-
cluding the Mini-Mental State Examination (MMSE) and the Montreal
Cognitive Assessment (MoCA), both of which seem to be effective for
detecting AD [94]. More specific tests can be used during follow-up to
determine the type and range of memory issues. For example, short-
term memory can be assessed by using the Digit Span, whereby patients
are required to recall an increasing sequence of numbers backwards or
forwards, while long-term memory can be assessed by adapting the
California Verbal Learning Test (CVLT [95]) or the Philadelphia Verbal
Learning Test (PVLT [96]) by including a 20-minute delay [97]. More
specific tests may include memory tests for faces [98] and paired as-
sociate learning [99]. Therefore, there is a mis-match between how
some important functions (e.g. memory) are examined in the clinic
compared to the laboratory. Often clinicians rely on tests that are easy-
to-use, easy-to-administer and are quick to complete. This is in contrast
with laboratory tasks that often require multiple trials administered
across hours or days.
Second, the difficulty in translating cognitive domains tested in the
clinic into behavioural animal tasks is that many screening tools, as
expected, rely on distinctively human characteristics and are therefore
difficult to translate directly to animal (particularly rodent) models.
Such domains include language (comprehension, writing, naming and
reading, e.g. tested as part of Addenbrooke’s Cognitive Examination
(ACE-III) [100], verbal fluency [101], abstract thinking (e.g. in the Brief
Kingston Standardised Cognitive Assessment Revised (BKSCA-R [102])
and copy and construction (e.g. in the Short Test of Mental Status
(STMS) [103],). However, there are a number of domains tested by the
various screening tests that can translate to animals but, unfortunately
these are seldom used as behavioural tasks with AD models. For ex-
ample, one of the most translatable tests for AD, and one that is con-
sidered the gold standard for memory in the clinic, is tests of episodic
memory [104,34]. As mentioned, episodic memory refers to the ability
to remember particular events in one’s life. For example, you might
remember attending a particular birthday party when you were young.
Episodic memory deficits are a common feature of AD and is considered
a sensitive cognitive measure of underlying pathophysiology, particu-
larly as episodic memory is thought to rely on a functioning hippo-
campus [105]. Despite tests of episodic memory being used as a diag-
nostic tool in the clinic, very few studies in animal models attempt to
model this, despite the existence of a number of analogous tasks. One
such test is the What-Where-Which (WWWhich) developed by Eacott &
Norman [106] and based on the work by Clayton & Dickinson [107]. In
this task animals, spontaneously explore an environment and attempt to
associate an object (What), its location (Where) and the environmental
context (Which). In another version, the WWWhen task, animals have
to associate an object (What), its location (Where) and the temporal
context (first or second occurrence – When [108]). Clear deficits in
episodic-like memory have been found in a number of different models
of AD that have used such tasks (e.g. Tg2576 APPswe [109],) and the
deficits observed seem to map to the progression of the underlying
pathophysiology (3xTgAD [110],).
Attentional and executive function deficits are other key features in
patients with AD and form part of the diagnosis criteria in the
Diagnostic and Statistical Manual of Mental Disorders (DSM–5). There
are a number of different tests that can be used for modelling attention
and executive functioning in animals, but again these are seldom used.
For example, one popular test is the five choice serial reaction time task
(5-CSRTT). This task was originally developed by Carli and colleagues
[111] but has been modified and adapted over the subsequent years. In
the task, the animal must detect and respond to brief light stimulus
emanating from an aperture (from a potential range of 5–9 openings) in
an operant box. Sustained attention can be measured by examining
when the animal responds to the incorrect hole versus the correct hole
from where the light appeared (errors of commission) or fails to re-
spond within a certain time (errors of omission). Other measures of
response inhibition including premature responding or continuing to
repeat previous mistakes (perseveration) may also be used to test ex-
ecutive functioning [39]. The task is similar to the Continuous Perfor-
mance test in humans [112], whereby participant are required to re-
spond only to a pre-specified target among a continuous sequence of
stimuli, or the alternative Sustained Attention to Response Task (SART
[113]), where participants are required to respond to every stimuli but
withhold their response on a pre-specified target. Despite being a robust
and valid task of attention, the 5-CSRTT is seldom used with animal
models of AD; however, the few that have used it, including Romberg
[114] with 3XTg-AD mice, have found performance deficits. However,
Bharmal and colleagues [115] did not find any difference in perfor-
mance at 5 months using TgTau-P301L mice, when compared to wild-
type. Although, the WWW, 5-CSRTT and other tasks are innovative and
are possibly provide measures that are analogous to some of cognitive
deficits observed in human patients, caution must always be applied
before direct comparisons can be made.
Third, the reverse could also be considered; some tasks used in
animal models may be applicable in the clinic, but seldom form part of
the screening or assessment process. For example, although AD is
considered mainly as a cognitive disorder, AD patients can develop
motor deficits, which may put patients at an increased risk of falling
[116]. Many rodent models do include tests of motor functioning, such
as, tests of balance, grip and strength. Motor impairments in the animal
models, including weakening grip strength (3xTg-AD [117],), balance
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issues and slower speed (5xFAD [63],), often match the motor deficits
observed in patients [118]. Recent evidence further highlights the link
between gait, balance and fall issues among those with AD [119] and
older adults, with a particular emphasis on the dual cognitive-motor
aspect of walking and motor co-ordination [120]. For example, there is
an increased risk of falling or gait changes if patients are required to
perform a cognitive task while walking (dual-task paradigm – [121]).
Simple gait analysis, dual-task measures and other tests of motor
functioning may be easily adopted in the clinic and offer a promising
approach for the detection and monitoring of AD progression.
Fourth, recent research has highlighted other potential behaviours
that are typically not considered in either animal models of AD or the
clinic. Some of these behaviours could be examined with relative ease.
For example, AD patients have been shown to have disturbed sleep
patterns and circadian rhythm deficits compared to healthy older
adults. Specifically, AD patients tend to show a reduced amplitude of
circadian rhythmicity, show a more fragmented sleep pattern, wake
with greater frequency during the night and sleep more during the day
[122]. Although, there are conflicting results on the exact nature of the
deficits, which seem to depend on the type and severity of cognitive
impairment [123], most studies find greater circadian deficits in cases
of severe AD and less impairments with MCI and milder forms of AD
[124]. Although there have been very few studies examining clock gene
expression in AD patients, Cermakian and co-workers [125] found
difference in PER1, PER2 and BMAL1 gene expression in post-mortem
brain tissue of AD patients compared to controls. Similarly, examining
sleep and circadian patterns and the underlying molecular expression
are rarely done in AD animal models; such behavioural measures could
easily be incorporated when testing. For example, using a simple run-
ning wheel, Stover [117] monitored the number of rotations that 3xTg-
AD mice completed in the wheel over a 7 day period and reported a
disrupted circadian rhythm compared to wild-type controls. While
Plucińska and colleagues [67] used a home-cage monitoring system to
examine distance moved in hBACE1 mice. Furthermore, it would be
very useful to correlate circadian and sleep disturbances with cognitive
measures, as well as, the underlying pathology.
Other behaviours, such as, depressive symptoms have long been
observed in patients with AD [126]. Despite this, there has been very
little examination of depression-like symptoms in animal AD models.
Tests such as the Tail Suspension Test or the Forced Swim Test [127]
may be easily incorporated as extra behavioural measures. In the Tail
Suspension Test, animals are usually suspended from a horizontal bar
by their tails from a certain height and for a specific time length (e.g.
˜120 cm above a table for 6min [128]), time spent immobile during this
period is used to measure depressive-like symptoms. Likewise, for
forced swim test animals are placed into a small container of water
(from which they cannot escape) for a certain period (e.g. 6 min.
[127],). The amount time that the animal stops swimming (i.e. im-
mobile) is taken as the animal having ‘given-up’ and an indicator of
depression-like behaviour. Very few studies have used such tasks in AD
animal models, but using the tail suspension test, Iascone and collea-
gues [129] showed that hAPP mice exhibited depressive behaviour at
13–15 months but not at 5–7 months.
5.3. Procedural issues
Many of the same tests are used very differently, despite the fact
that they are supposedly testing the same function. Using a non-stan-
dardised testing apparatus and procedures make it very difficult for
researchers to compare results, to allow for replication of experiments
and the development of norms. This is particularly important if we are
trying to compare various models of AD. Using different models with
different procedures and/or a different testing apparatus, how can
findings be generalised across multiple AD models and then translated
to humans and the clinic? In Table 1 we highlight how different labs use
the same task. This is not meant to be an exhaustive list but merely used
to point out discrepancies between both the test apparatus (e.g. the size,
shape, physical dimensions) and the procedure used (e.g. number of
trials, inter-trial-interval length, trial length etc).
From our sample of the literature, the most consistent behavioural
task used, both in terms of the apparatus and procedure, is the elevated
plus maze. The time allowed for mice to explore the maze is generally
5min (with just one of our studies giving 8min, [57]). Likewise, the
apparatus used is very standard with a typical arm length, width and
height (of closed arms) of 30 cm, 5 cm and 15 cm, respectively. The only
major difference between the various studies is in terms of the height
that the apparatus is elevated, ranging from 50 cm to 100 cm. This may
be an issue as ‘elevation’ and an animal’s fear of open spaces (including
the third dimension) are critical to the task itself.
The next task that remains relatively consistent between research
groups is the water maze task. All experiments use a circular pool; while
the diameter of the pool does range between 100 cm–180 cm, most of
our sample experiments have a pool diameter of 120 cm. Similarly,
although the size of the platform ranges between 7 cm–17 cm in dia-
meter, the relative platform size to the overall pool size is approxi-
mately 8% (although see [130] at 12%). Note, that these values are
used typically with mice. For rats, the pool is often 180–200 cm s in
diameter (see [47] for example). Size is critically important as there
have been reports to demonstrate that if the pool is too small relative to
the goal size, rats are able to solve the water maze without the use of
spatial cues [131]. In terms of procedures, the maximum time allowed
for a given trial is typically 60 s (although both O’Leary [63] and Plu-
cinska [67] allowed 90 s for their trials). Where the biggest difference
between the experiments arise is in terms of the training procedure;
animals can receive anywhere between 10 trials [132] to 30 trials (6
trials/day for 5 days [130],). Most authors tend to give 4 trials/day for
4 or 5 days (i.e. 16–20 trials, see Table 1). The worrying aspects about
some of the water maze procedures used is that longer trials or multiple
trials with a short inter-trial interval, can lead to reduced swim speeds,
most often in mice and aged rats. While it is possible this is due to
fatigue, the more likely explanation is hypothermia due to the short
inter-trial interval [133,134]
From an examination of our sample of studies, the rotarod test for
motor co-ordination is very consistent in terms of the apparatus used,
possibly because rotarods are commercially available and are fairly
standardised. However, the manner in which it is used differs across
research groups. For example using mice, the baseline rotation rate can
range from 0 rotations per minute (RPM, i.e. not rotating) to 4 RPM,
while the maximum rotations can range from 40 to 48 RPM. The time
allowed to reach the maximum rotation speed also differs from 5 to
10min (see Table 1, first column). Similarly, many authors simply use a
single trial [54], while others train animals across trials and days [67].
In a similar fashion, the balance beam also tends to be consistent in
terms of the apparatus used – most authors using mice have a beam of
approximately 80–100 cm in length, 2–3 cm in width and 30–50 cm s in
terms of elevation. However, the training procedure differs across ex-
periments, with some authors using a single 2-minute trial [117], while
others use multiple training trials across days [130]. At the more in-
consistent end for both apparatus and procedure used are the T/Y maze
task and the novel object recognition task. For example, Davis [135]
used a T-maze with arms of 19 cm in length and 4.5 cm wide and 9.5 cm
high walls (with mice). Whereas, Olmos-Alonso [136] used arms of
30× 10×29 cm. Similarly, some authors simply allow animals to
explore the maze for a set period [67]; while others train across mul-
tiple trials and days [136]. The novel object task also varies in its
procedures - from allowing animals to habituate across days [70] to a
single trial [65], from separating training and testing sessions by min-
utes [61], an hour [54] or 24 h [65]. In general, two items are used
during testing, one of which is then replaced. Authors seldom describe
the items; responses to plastic or more natural objects (e.g. stone or
wood) may produce very different reactions and these are not usually
considered. Finally, despite being one of the most popular tests used for
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Comparison of the different apparatus and procedures used by different laboratories when performing the ‘same’ test on laboratory animals.
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AD models (see Fig. 1a), the open field test is the most inconsistent in
our sample. For example using mice, the apparatus can range from a
square box [65], a circular arena [66] to a home cage [136], as such,
the size of the arena changes dramatically (e.g. 50×50 cm,
35×30 cm, 76×76 cm, 123 cm in diameter and 46×43 cm, see
Table 1). In addition, the time allowed to explore the arena varies from
5, 10, 15 and up to 30min; this is often irrespective of the size of the
arena. Such inconsistency makes direct comparisons between AD
models very difficult, especially if such an AD model displays hyper-
activity (see discussion above).
6. Recommendations
Although animal models play an important role in understanding
the mechanisms of a neurological disorder, it is clear from the discus-
sion above that the choice and adequacy of behavioural tests used is
critical to allow the interpretation of results. We detail below some
recommendations and potential developments in the field of beha-
vioural testing in models of Alzheimer’s disease, that are also applicable
to many other neurodegenerative disorders.
6.1. Better behavioural controls and experimental design
While there are guidelines and procedures for conducting pre-clin-
ical testing, they are not always complied with. This has led to con-
siderable criticism of animal models as the largely positive results from
pre-clinical testing have not translated into clinical results and this
needs to be improved. Strict use of the existing animal model guide-
lines, such as ARRIVE (‘Animal Research: Reporting of In Vivo
Experiments’), is strongly recommended and vital to improve the
translatability of in vivo experiments [137]. Good experimental design,
including randomisation and blind testing is critical; however, it is not
always done, or reported in publications [138]. For example, the use of
blinding of experimenters to treatment group allocation is important to
ensure that in all tests, including behavioural assessment, there is no
bias which could affect the outcome of the tests, including the well-
characterised experimenter effects illustrated by Rosenthal [139].
However, as with randomisation, this is not always clearly described in
the methods. This was clearly highlighted by Egan and colleagues who
carried out a meta-analysis of interventions in transgenic mouse models
of Alzheimer’s disease. Amongst others within this study, they showed
Table 1 (continued)
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that of the publications they examined, less than 25% reported blinding
of experimenters [7]. In the same study, it was demonstrated that when
randomisation and blinding were conducted in studies, these led to
smaller effect sizes. Careful sample size calculations should also be
made to ensure the experiment is sufficiently powered to detect any
difference (also an element that is often overlooked [7]).
Linked to good experimental design is having adequate behavioural
controls. While most studies use wild-type or a saline condition as a
control for various animal model, researchers seldom if ever control for
behaviour or highlight the precise behaviour they wish to examine.
Many behavioural tasks tap into a range of functions, deficits in any one
of these functions may be misinterpreted as a feature of the diseased
model. For example, an animal that does poorly on the water maze task
does not necessarily imply spatial learning deficits. Have motor, visual,
motivation, stress and other factors been completed ruled out? If an AD
model tends to show motor deficits, does a lack of movement in the
Table 2
Suggested dimensions and procedures for various tasks.
Task Species Apparatus dimensions (approx.) Procedure Sample
references
Motor
Rotarod Mice Rod of 3 cm in diameter, supported 30 cm above the
base. The surface of rod is knurled in parallel ridges to
help grip.
2 flanges (20–30 cm in diameter) or more (to
accommodate multiple animals to be tested
simultaneously) are separated by a distance of 3–6 cm.
Habituation period:
1min trial on static rotor. After 15 min break, another 1 min trial at
4 r.p.m.
To test motor performance:
A single 300 s trial with rotor accelerating from 4 r.p.m to 40 r.p.m is
used.
Latency to fall is recorded.
For motor learning:
3× 300 s trials with ITI of 15 min. Rotor increasing from 4 to
40 r.p.m during each trial.
[141]
[142]
Rats Rod of 7–8 cm in diameter. As above [143]
Balance Beam Mice Wooden beam of 80-100 cm in length, 1-2 cm in width
and 30–50 cms in terms of elevation.
Training
Mice given 3 trials to cross beam. With 10min break between each.
Time taken to cross beam is measured.
Test
Average time to cross beam taken from 2 successful trials.
[144]
Rats Wooden beam of 100-120 cm in length, 2-3 cm in width





Mice ˜120 cm diameter circular arena with height of 50 cm.
Circular or square platform of 10–12 cm in diameter or
10 cm2, respectively. Located 0.5–1 cm below water
surface.
Search area:target ratio of ˜117:1.
Allow 1min for each trial.
Inter-trial interval of 15 s.
4 trials per day for 5 or 6 days.
(20–24 trials).
Latency to find hidden platform is measured.
[146]
Rats ˜200 cm diameter circular arena with height of 50 cm.
Circular or square platform of 10–12 cm in diameter or
10 cm2, respectively. Located 1-2 cm below water
surface.
Search area: target ratio of ˜346:1.
Allow 1 or 2 min for each trial.
Inter-trial interval of 15 s.
4 trials per day for 5 or 6 days.
(20–24 trials).





30 cm length × 10 cm width.
Goal arm (X2)
30 cm length × 10 cm width.
Wall height 20 cm
Continuous trial procedure
Allow min 5 min. to explore
Sequence of arms is recorded
Discrete trial procedure
Place animal in start arm and allow to choose a goal arm. Confine
animal in goal arm for 30 s.
Replace animal in start arm and allow animal to pick from the two
goal arms. Number of correct choices noted. Each trial should last
< 2min. 2/3 trials across multiple days is suggested.
[147]
Rats Start alley:
50 cm length × 16 cm width.
Goal arm (X2)
50 cm length × 10 cm width.
Wall height 30+ cm
As above
Novel Object Mice/rats There is no standard size or shape but a square or
rectangle apparatus of
dimensions between 30 cm×30 cm × 30 cm and
50 cm×50 cm × 50 cm are typically used.
2 objects
(key feature is to maximise the difference between objects
without inducing a strong preference for one).
Objects of different shape, texture, size and brightness
can be used. Rodents have a difficulty in discriminating
colour, so this should be avoided.
Habituation
Allow animal to explore empty arena for 5 min.
Familiarisation
24 hours later, allow animal 5 min to explore arena that now
contains the two objects, located at 5 cm from wall.
Time exploring each and both objects is recorded.
Test
Replace the two familiar objects, one with a triplicate copy (to ensure




Elevated plus maze Mice 4 arms (two open without walls and two enclosed by
15 cm high walls). Each arm 30 cm long and 5 cm wide.
Elevation 40 cm above ground
5min exploration.
Time and Number of entries into open and closed arms should be
recorded.
[149]
Rats 4 arms (two open without walls and two enclosed by
30 cm high walls). Each arm 50 cm long and 10 cm wide.
Elevation 50 cm above ground.
5 min exploration.
Time and Number of entries into open and closed arms should be
recorded.
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exploration task or slowness in the water maze task reflect a lack of
motivation or learning, respectively? Researchers need to be aware of
the limitations of the various tasks and use appropriate behavioural
controls (see [89]).
6.2. Standardisation of testing
One of the major aspects that we highlighted in this review was the
lack of procedural consistency in many of the behavioural tasks cur-
rently in use. If different research groups are using different procedures
(even if the apparatus is similar), it makes comparison and replication
of results very difficult. There are some excellent reviews and re-
commendations of protocols currently available in the literature and
these match closely with the consistently used procedures identified in
our sample. In Table 2 we provide a summary of some of these protocols
and appropriate references for more detailed descriptions. We can not
describe all tasks or the range of different protocols that could be used
to examine various functions, even using the same tool (e.g. spatial
working memory, reference memory, procedural memory and cued
memory can be all tested in the water maze task by using different
procedures). However, at a minimum we recommend researchers to
adhere to such published and well validated protocols that have been
consistently shown to work across various AD models.
6.3. Interaction between stakeholders
Public-patient involvement (PPI) is increasingly recognised as an
important aspect of research, especially human work. Here patients/
public work closely with the researcher to help set priorities and design
experiments. Research is said to be done ‘with’ patients or members of
the public rather than ‘for’ them. While a full PPI may not be appro-
priate with some animal work, researchers using animal models should
link in with patient groups and interact with clinical practitioners as
much as possible. This will help researchers to understand behavioural,
cognitive and other issues in practice and may help to overcome some
of the translational issues discussed above. Furthermore, while some of
the animal models used are relevant to the clinic, many are not.
Therefore, there is a need to re-evaluate the models and behavioural
tests used to ensure they are appropriate and relevant. For example, as
described above, there are many behavioural tests that are relevant to
the clinical condition, but they are often the least popular measures
used. Consequently, more careful consideration and planning of phe-
notypic measurement is required. It is important to note that interac-
tions between patients, clinicians and researchers should not be uni-
directional but learning should be reciprocated. For example, although
spatial navigation impairments are observed in patients and in animal
models [34], these deficits are currently not routinely tested in the
clinic. This can be achieved with greater interaction between all sta-
keholders.
6.4. Innovative in design of tests
Acknowledging that there is often a difficulty in directly translating
many uniquely human tests to animals, particularly those with a strong
language component, researchers need to be innovative in their ap-
proach. Animal tasks such as the WWWhen task or the five choice serial
reaction time task are excellent examples of directly translating epi-
sodic memory and attention deficits observed in AD patients. However,
caution is still required as any novel test would need to be appropriately
validated. One approach to doing this with models of any of the neu-
rodegenerative conditions would be to test the model with a therapeutic
agent that has been demonstrated to be clinically effective in the stage
of the condition you are examining, though a difficulty here is the re-
lative lack of such agents.
7. Conclusions
Animal models have made a significant contribution to our under-
standing of the changes that occur in neurodegenerative disorders,
particularly Alzheimer’s disease, as they have been used to determine
underlying pathological mechanisms, determine the changes induced
by genetic modification and to evaluate the efficacy of putative ther-
apeutic agents. However, their utility is limited as they are not able to
recapitulate all aspects of the complex neurodegenerative changes and
positive pre-clinical results have not yet translated to the clinic. While
one possible reason for this may be a lack of external validity or gen-
eralisability of a model, it is also clear that there is also a bias in
publication that results in pre-clinical studies showing over-promising
effects in the clinic [140,7]. While there may be many reasons for this,
one possibility is the fact that it is easier to publish positive results
rather than neutral or negative results, this publication bias still reduces
their applicability to the clinical situation. Furthermore, the complexity
of behavioural models coupled with procedural and interpretational
issues have cast doubt on the usefulness of such models for predicting
clinical efficacy
Based on the above, and reviews by others, there are a number of
key considerations to improve the translation from animal models to
the clinic. First, choosing a model, careful design of the experiment and
being aware of its limitations is critical. The models can tell us a lot
about, for example, mechanistic pathways in a particular neurodegen-
erative disease, but cannot represent the full complex disorder. Second,
having chosen the model, a clearly defined and validated protocol
should be followed for the model and careful notice taken of the
ARRIVE guidelines. Following clear consistent steps will ensure that
better and more realistic pre-clinical studies are conducted and pub-
lished, which will lead to greater translation to the clinic.
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